Short on label expansions, Pfizer nabs FDA OK for new, once-daily Xeljanz

Short on label expansions, Pfizer nabs FDA OK for new, once-daily Xeljanz

But in the meantime, it's rolling out a new extended-release formula for the disease it's already approved to treat. Wednesday, the FDA approved an extended-release formulation of Xeljanz, a second-line, oral rheumatoid arthritis therapy. Patients can

(Visited 1 times, 1 visits today)
4
Like
Save

Comments

Comments are disabled for this post.